Abstract Infection by Staphylococcus aureus is on the rise, and there is a need for a better understanding of host immune responses that combat S. aureus. Here we use DNA barcoding to enable deep sequencing of the paired heavy-and light-chain immunoglobulin genes expressed by individual plasmablasts derived from S. aureus-infected humans. Bioinformatic analysis of the antibody repertoires revealed clonal families of heavy-chain sequences and enabled rational selection of antibodies for recombinant expression. Of the ten recombinant antibodies produced, seven bound to S. aureus, of which four promoted opsonophagocytosis of S. aureus. Five of the antibodies bound to known S. aureus cell-surface antigens, including fibronectin-binding protein A. Fibronectin-binding protein A-specific antibodies were isolated from two independent S. aureus-infected patients and mediated neutrophil killing of S. aureus in in vitro assays. Thus, our DNA barcoding approach enabled efficient identification of antibodies involved in protective host antibody responses against S. aureus. Published by Elsevier Inc. 
Introduction
Staphylococcus aureus, the second-most common bacterial pathogen isolated from humans, is estimated to cause over half a million cases of invasive infection and over 18,000 deaths annually in the United States [1] [2] [3] . The emergence of multidrug-resistant strains, such as methicillin-resistant S. aureus (MRSA), has complicated treatment procedures, prompting research into vaccines and novel immunotherapies. Still, how S. aureus interacts with the human immune system is unclear, and no vaccines are currently approved for preventing or treating S. aureus infections [4] . Antibody titers against S. aureus proteins increase during acute infection [5] , and patients with immunoglobulin deficiencies are more susceptible to S. aureus infections [6] , suggesting that the host antibody response is important for containing S. aureus. However, the critical S. aureus antigens that elicit protective host immunity remain undefined, with little or no correlation observed between disease severity and levels of serological antibodies against known S. aureus virulence factors [7] .
Antibodies circulating in the blood are produced by plasma cells and their transient B-cell precursors (termed plasmablasts). After successfully completing antigen-dependent affinity maturation, naïve and memory B cells differentiate into plasmablasts and proliferate rapidly in the blood before trafficking to infected tissues. Although plasmablast frequencies in peripheral blood are typically low before and after antigen stimulation of an immune response (~0.2% of circulating B cells), they can account for over 30% of circulating B cells during an infection [8, 9] . Thus, the expansion, specificity and accessibility of circulating plasmablasts provide a powerful approach to characterize the active B-cell response.
Accurate identification of the affinity-matured and expanding B-cell lineages requires methods that can both approximate the frequency of B cells expressing similar variable-region genes and recover the endogenous heavyand light-chain variable-region pairings from individual B cells. Previously published high-throughput approaches that sequence only the heavy-chain or heavy-and light-chain complementarity-determining-region 3 (CDR3) from bulk B cells and/or do not implement any methods to normalize the relative abundance of sequencing reads to the number of cells expressing a given sequence [10] [11] [12] [13] , making it difficult to determine whether highly represented sequences are the result of antigen-driven B-cell clonal proliferation or of sequence biases introduced during PCR amplification. Additionally, the inability to recover heavy-and light-chain pairs precludes the functional characterization of the endogenous antibodies.
To overcome these limitations, we use a novel DNA barcode system to sequence the paired heavy-and light-chain antibody genes expressed by individual plasmablasts, and in doing so to accurately determine the proportion of plasmablasts that express specific germline sequences and somatic mutations. Herein we sequence the endogenous antibodies expressed by individual plasmablasts circulating in the blood of individuals with S. aureus bacteremia, bioinformatically identify clonal families of antibodies sharing heavy and light chain VJ sequences, and recombinantly produce and characterize of the binding and functional properties of representative antibodies.
Material and methods

Single-cell sorting of peripheral blood plasmablasts
Blood was collected from individuals with culture-confirmed S. aureus bacteremia after after informed consent was obtained and under human subject protocols approved by the Investigational Review Board at Stanford University. For all individuals, blood specimens were obtained within 24 h after the initiation of standard-of-care antibiotic treatment. PBMCs were isolated using a Ficoll layer and stained with CD3-V450 (BD 560365), IgA-FITC (AbD Serotec STAR142F or Miltenyi #130-093-071), IgM-FITC (AbD Serotec STAR146F), IgM-APC (BD 551062) or IgM-PE (AbD Serotec STAR146PE), CD20-PerCP-Cy5.5 (BD 340955), CD38-PE-Cy7 (BD 335808), CD19-APC (BD 340437) or CD19-Brilliant Violet 421 (Biolegend 302233), and CD27-APC-H7 (BD 560222). IgG + plasmablasts were gated on CD19 +/ intCD20 − CD27++CD38++IgA − IgM − cells and individually sorted using a BD FACSAria III into a 96-well PCR plate containing a hypotonic lysis buffer (10 mM Tris-HCl pH 7.6) containing 2 mM dNTPs (NEB), 5 μM oligo(dT) 20VN, and 1 unit/μl of Ribolock (Fermentas), an RNase inhibitor.
Reverse transcription (RT) and Polymerase Chain Reaction (PCR) with well-ID and plate-ID adaptors
We added 6 mM MgCl 2 with Ribolock, Superscript III (Life Technologies), and 1 μM final concentration of the appropriate well-ID oligonucleotide barcode to sorted plasmablast plates and performed RT at 42°C for 120 min. RT products from each plate were pooled, extracted with phenol-chloroform-isoamyl alcohol, and concentrated with Amicon Ultra-0.5 30 kDa (Millipore) units.
We used Phusion Hot Start II DNA polymerase (NEB/ Fermentas) for both the first PCR (PCR1) and the second PCR (PCR2). The following PCR reaction conditions were used: 200 μM of dNTPs, 0.2 μM of primers, 0.2 U of Phusion polymerase, 4% DMSO, and 2 μl of RT product. PCR1 was performed with forward (FW) primers containing, at their 5′ end, a plate-ID barcode oligonucleotide, as well as a 454 Titanium adaptor, and with gene-specific reverse primers (GSP) for amplifying the gamma, kappa, and lambda chains. PCR2 was performed with FW primers containing a 454 Titanium adaptor at their 5′ end and reverse GSP containing a plate-ID barcode oligonucleotide and a 454 Titanium adaptor at their 3′ end.
We pooled the amplified DNA, gel purified them, and purified them with Ampure XP beads (Beckman Coulter). Amplicon concentrations were determined by using Picogreen DNA assay kits (Invitrogen), and amplicons were sent to Roche for 454 sequencing.
Bioinformatic analysis and generation of dendrograms
Sff output files from 454 sequencing, containing sequences and quality scores for each nucleotide, were read into Python by using the Biopython package, and sequences were grouped and parsed into separate sff files on the basis of their plate-and well-ID combinations. Consensus sequences corresponding to plasmablast heavy-and light-chain sequences were generated using Newbler 2.6. Where multiple assemblies occurred per well, an assembly was accepted if it represented N 50% of all reads in the given well. Otherwise, we disregarded all reads from that well to preclude instances where a well contained more than one cell and to account for sequencing errors introduced during pyrosequencing.
To assign V(D)J families for consensus sequences, we analyzed heavy-and light-chain sequences with the IMGT HighV-QUEST15 database [14] to predict germline allele usage, germline sequence recombination, and shared mutations relative to the germline sequence.
To generate dendrograms, we first binned heavy-and light-chain sequences according to their V-gene usage and aligned them with Muscle28 [15] . They were clustered with PhyML maximum-likelihood clustering and rooted by their germline V gene [16] . Each V-gene phylogenetic tree was then arranged by heavy-chain V-gene families and drawn by using ETE30 [17] .
Cloning and expression of recombinant antibodies
Antibodies representative of the heavy-chain families were selected for expression on the basis of (1) having a corresponding light-chain plate-and well-ID combination and (2) being the heavy-and light-chain pair most representative of the consensus sequence of the family. Gamma heavy chains were inserted into vector pEE6.4 (Lonza), and kappa and lambda light chains were inserted into vector pEE12.4 (Lonza). We used well-ID-specific FW primers and GSP reverse primers to selectively amplify cDNA for insertion into the expression vectors. Heavy-and light-chain sequences were cloned by first inserting the sequences of the antibody constant regions into the vector and inserting the leader and V(D)J sequences by using standard molecular biology techniques.
Expression of recombinant antibodies was performed by dual transfection of heavy-chain-containing pEE6.4 constructs and light-chain-containing pEE12.4 constructs in 293T cells, using Lipofectamine 2000 (Life Technologies). Antibodies were purified from culture supernatants by using Protein A Plus agarose beads (Pierce), eluted with IgG elution buffer (Pierce), and quantified by BCA Protein Assay (Thermo Scientific).
Bacterial culture and preparation
S. aureus Wood46 (ATCC 10832) were grown in LB to early-logarithmic (0.25 optical density units (ODU)), mid-logarithmic (0.5 ODU), or stationary (2.0 ODU) growth phases, as determined by spectrophotometry at 550 nm. We pelleted bacteria by spinning at 5000 g for 10 min, and resuspended them in 0.1% sodium azide in PBS to halt bacterial metabolism and to capture snapshots of the protein expression.
For experiments in which S. aureus were grown in the presence of fibroblasts, NIH/3T3 mouse embryonic fibroblasts (ATCC CRL-1658) were cultured in DMEM (ATCC supplemented with 10% FBS, 0.6 μg/ml L-glutamine, 0.2 U/ml penicillin, and 0.2 μg/ml streptomycin and stimulated with 300 pM recombinant mouse TGF-β1 (R&D Systems) in culture media minus antibiotics for 72 h. S. aureus Wood46 were grown to stationary phase in LB resuspended in DMEM, and incubated with NIH/3T3 cells for 2 h. NIH/3T3 cells were then lysed with hypotonic buffer and washed, and bacterial cells were resuspended in 0.1% sodium azide in PBS.
For experiments with Escher coli, DH10B E. coli were grown in LB for 14 h, pelleted, and resuspended in 0.1% sodium azide in PBS.
S. aureus lysate dot-blot analysis
To prepare S. aureus lysates for dot-blot, 0.25 g of growth phase-specific bacteria in sodium azide (dry weight) was incubated with B-PER lysis solution (Thermo Scientific), 1 × Halt protease inhibitor, and 0.05 μg/ml freshly prepared lysostaphin (Sigma) for 35 min at 37°C, then for 15 min at ambient temperature with shaking. Samples were centrifuged at 15,000 g for 15 min at 4°C, and the supernatants were collected and quantitated by BCA assay.
Dot-blot was performed on 0.45 μm nitrocellulose transfer membrane with the Bio-Dot Microfiltration Apparatus (Bio-Rad) as per manufacturer's instructions. 500 ng lysate in 50 μl TBS was spotted per well and blocked with 3% BSA-TBS. Recombinant test antibodies were diluted to 2 μg/ml in 0.1% TBST with 3% BSA and added to appropriate wells. 1:15,000 goat anti-human IgG-Fc HRP (Bethyl Laboratories) secondary antibody was used for detection, and dot-blots were visualized with West Femto Substrate (Thermo Scientific).
Flow cytometric analysis of antibody binding
We blocked sodium-azide-treated S. aureus Wood46 or DH10B E. coli cells with 1% BSA-PBS for 45 min at 4°C, then added 10 μg/ml of recombinant test antibodies in 1% BSA-PBS for 60 min at 4°C, washed three times with 1% BSA-PBS, and incubated for 20 min at 4°C in the dark with 1:5 mouse anti-human-IgG PE secondary antibody (BD Pharmingen) diluted 1:5. Cells were washed three times with PBS, and antibody surface binding was detected with an LSR Fortessa.
S. aureus antigen array analysis
A full-proteome microarray of the S. aureus USA300 strain-a strain prevalent in community-acquired S. aureus [18] containing approximately 2700 S. aureus proteins per array (Antigen Discovery Inc., Irvine, CA) was used for determining the specificity of recombinant antibodies derived from S. aureus-infected humans. Conditions used for preparing, probing, and analyzing the microarray chips were performed as described in [19] .
S. aureus antigen ELISA
We used ELISA to determine whether the recombinant antibodies derived from bacteremic individuals bind to purified S. aureus antigens. We coated Nunc Maxisorp plates with 1.5 μg/ml lipoteichoic acid or peptidoglycan purified from S. aureus (Sigma Aldrich) in pH 7.4 PBS and blocked the plates overnight with PBS containing 1% BSA. Recombinant antibodies were added at 1 μg/ml and diluted serially 3 ×. After washing with PBST (PBS with 0.05% Tween20), antibody binding was detected by using an HRP-conjugated goat anti-human IgG-Fc antibody and TMB substrate. Absorbance was measured with a SpectroMax M5 spectrophotometer at 450 nm.
Flow cytometric analysis of S. aureus opsonophagocytosis
To label sodium-azide-treated S. aureus for detection of bacterial internalization, we washed and resuspended the bacteria in PBS, and then incubated them with 2 μl of CellTrace CFSE (Invitrogen) for 30 min at 37°C with constant shaking at 250 rpm. CFSE-staining was stopped by incubating the cells for 5 min with 500 μl ice-cold PBS and washing them three times in PBS.
We cultured THP-1 human monocyte-like cells (ATCC TIB-202) in RPMI-1640 supplemented with 10% FBS, 0.6 μg/ml L-glutamine, 0.2 U/ml penicillin, and 0.2 μg/ml streptomycin at a density below 5 × 10 5 cells/ml to minimize macrophage differentiation [20] .
To assess opsonophagocytosis, we incubated 2 × 10 6 CFSE-labeled S. aureus for 60 min with 10 μg/ml antibody in 1% BSA-PBS, washed them three times, and resuspended them in pre-warmed 25 μl RPMI-1640 with 1% FBS. 100 μl THP1 cells were then added to the CFSE-labeled S. aureus and incubated for 40 min at 37°C with shaking at 200 rpm. Phagocytosis was stopped by adding 1 ml ice-cold PBS to the cell mixture and centrifuging it at 350 g for 3 min at 4°C. Cell-surface and extracellular fluorescence were quenched by resuspending the cell pellet with 200 μl ice-cold Trypan Blue (2 mg/ml in PBS) in 2% paraformaldehyde [21] . N 10,000 THP1 cellular events were counted with an LSR Fortessa.
Neutrophil bactericidal assay
HL-60 cells were cultured with RPMI-1640 supplemented with 10% FBS, 0.6 μg/ml L-glutamine, 0.2 U/ml penicillin, 0.2 μg/ml streptomycin, and 50 μM β-mercaptoethanol. HL-60 cells were differentiated for 96 h in culture media containing 1.3% DMSO and 2.5 μM all-trans retinoic acid as previously described [22] and resuspended in HBSS supplemented with 10% human AB serum at 10 6 cells/ml. S. aureus Wood46 were grown in LB overnight at 37°C, and resuspended in HBSS with 10% human AB serum at 10 6 bacteria/ml, and 10 μg/ml recombinant test antibody was added to the bacteria. HL-60 cells and bacteria were then added at a 1:1 volume ratio and incubated for 1 h at 37°C with shaking. Three 1:10 serial dilutions of the HL-60: bacteria mixture were performed in PBS. Bacteria were plated on TSA plates (BD), grown at 37°C for 16 h, and bacterial colony-forming units were counted.
Results
Plasmablast levels are elevated during S. aureus acute bacteremia
Previous studies detected transient elevations in levels of peripheral blood plasmablasts that peak approximately 7 days following an immune challenge [9] . We investigated whether patients with community-acquired S. aureus bacteremia and acute clinical manifestations exhibit elevated plasmablast levels (CD19 +/int /CD20 − /CD27 ++ /CD38 ++ ) in peripheral blood. All individuals with S. aureus bacteremia had greater than 1% plasmablasts per total peripheral blood B cells, with a mean of 3.2%, indicating a ten-fold increase above normal plasmablast frequencies (Figs. 1A and B) .
IgG plasmablast single-cell sequencing reveals expression of antibody families with shared gene segments
To obtain paired heavy-and light-chain antibody sequences from individual single-cell sorted IgG + plasmablasts, we utilized a DNA barcoding method that our laboratory developed [23] . This method uses the dual function of Superscript III reverse transcriptase to synthesize cDNA from the mRNA of single cells, and to thereby enable tagging of the newly generated cDNA with well-specific (and thus cell-specific) oligonucleotide barcodes at the 5′ end of mRNA via template switching [24] . Primers containing plate-specific barcodes were then added and hybridized to a universal linker sequence flanking the 5′ end of the well-IDs. The resulting double-tagged amplicons were sequenced by 454 GS FLX +, generating~800,000 reads per run, with a mean read length of 600 base-pairs (bp) for heavy chains and 480 bp for light chains. These lengths were sufficient for the recovery of the entire V(D)J region of heavy and light chains spanning the Framework 1 and Framework 4 conserved regions. After discarding any incomplete V H and V L sequence assemblies, we generated dendrograms of each patient's plasmablast heavy-chain (V H dendrograms) and paired heavyand light-chain (V H :V L dendrograms) repertoire to visualize the number of antibodies using identical germline IGHV genes, which we define as an IGHV family ( Fig. 2 and Supplemental  Fig. S1 ). Because the V H dendrograms contained more sequences than the paired-chain dendrograms, we focused on plasmablast heavy-chain dendrograms in determining which immunoglobulin rearrangements were preferentially selected for in response to S. aureus infection.
For patients 1 and 2, who mounted robust plasmablast responses and successfully cleared their clinical infections (and from whom we obtained 120 and 125 full-length V H sequences, respectively), we analyzed the extent to which IGHV families containing more than five V H sequence assemblies also used the same IGHJ genes (Fig. 2) . In patient 1, nine IGHV families contained more than five recovered V H sequences, and five of these IGHV families used the same IGHJ gene in at least 50% of the sequences ( Fig. 2A) . Of the nine IGHV families, IGHV3-7 had the highest percentage of shared germline IGHV and IGHJ usage (64% IGHJ4). Notably, five of the seven V H sequences in the IGHV5-a family in patient 1 used IGHJ6 and had highly similar somatic mutations in both the heavy-and light-chain variable regions, suggesting that the five plasmablasts containing these V H sequences may have arisen from the same B-cell lineage (Supplemental Fig. S2 ). Patient 2 displayed greater heterogeneity in the combination of IGHV and IGHJ genes used in the rearranged sequences. Six IGHV families contained more than five V H sequences and family IGHV3-30 had the highest percentage of shared germline IGHJ usage (40% IGHJ4) (Fig. 2B ).
Rational selection of highly represented antibody sequences for recombinant antibody expression
Because we observed that certain IGHV and IGHJ alleles were combinatorially selected for during the response to S. aureus infection and thus appeared more frequently in the antibody repertoire, we asked whether antibodies encoded by these sequences can bind to S. aureus. We selected representative antibodies from IGHV families with highly shared IGHJ for recombinant human monoclonal IgG expression (S3, S4, S5, S8, S10) (Supplemental Fig. S1 and Table 1 ). For comparison, we also expressed five V H :V L pairs that did not contain shared intra-patient IGHV and IGHJ usage (S1, S2, S6, S7, S9), which we term singletons. levels of protein A, thereby minimizing non-specific binding to immunoglobulin. Because bacterial gene expression differs significantly between early logarithmic (early-log) and stationary growth phases [25] , we assessed antibody binding to lysates from bacteria at both growth phases.
Quantitative dot-blot analysis revealed that the antibodies S2, S4, S5, S6, S8, and S10 bound to S. aureus in the early-log growth phase with at least three-fold greater intensity as compared to the lysis buffer alone, whereas only S3 bound strongly to S. aureus in the stationary phase (Fig. 3A) . We next used flow cytometry to determine whether any of the recombinant antibodies could bind to the surface of the S. aureus Wood46 strain at three different growth phases. We found that antibody S3 bound to bacteria at all growth phases, whereas S8 bound to bacteria at early-log and mid-log phases, but not at the stationary phase (Supplemental Fig. S3 ). Antibodies S2, S4, S5, S6 and S10, which bound S. aureus in the dot-blot assay, did not bind S. aureus in any of the growth phases using the standard growth medium alone (Fig. 3B) .
During infection, S. aureus often adhere to connective tissues and extracellular matrix proteins [26] . Fibroblasts are the most abundant cell type in soft connective tissue and secrete many of the factors that comprise the extracellular matrix [27] . Therefore, we sought to determine whether culturing S. aureus in the presence of fibroblasts more closely resembles the environment of S. aureus colonization and thereby induces differential regulation of S. aureus surface antigens. Flow cytometric analysis of S. aureus Wood46 grown in the presence of TGF-β-stimulated NIH/3T3 fibroblasts revealed that not only the S3, but also the S6 and S10 recombinant antibodies can bind robustly to the bacterial surface ( Fig. 3C and Supplemental Fig. S3 ). None of these antibodies bind to E. coli (Supplemental Fig. S3) . Importantly, in all surface-binding experiments, two recombinant antibodies that recognize the trivalent inactivated flu vaccine did not bind to S. aureus, indicating the specificity of the antibody binding. Collectively, our antibody-binding analyses show that all five antibodies from clonal families with shared intra-patient IGHV and IGHJ usage (i.e., S3, S4, S5, S8, and S10) bind to S. aureus, whereas only two of the five antibodies from families lacking common IGHV and IGHJ usage (i.e., S2 and S6) bind to S. aureus (Table 1) . Further, our results demonstrate differential binding of individual antibodies to S. aureus at different growth phases.
Recombinant antibodies derived from peripheral blood plasmablasts bind to S. aureus virulence factors and surface antigens
We used a full-proteome microarray of the S. aureus USA300 strain (Antigen Discovery, Inc.)-a strain prevalent in community-acquired S. aureus outbreaks [18] -to identify the targets of these S. aureus-specific recombinant antibodies. Antibodies S6 and S10 bound to SAUSA300_2441 and SAUSA300_2441-s1 with four-fold intensity over background (Fig. 4A ). These two hits correspond to different segments of the same protein, fibronectin-binding protein A (FnBPA). FnBPA is a MSCRAMM (microbial surface components recognizing adhesive matrix molecules) expressed on the bacterial membrane that allows the bacteria to attach to the extracellular-matrix proteins fibronectin and fibrinogen and thereby promotes invasion of host tissues [28] [29] [30] . Subsequent binding analyses showed that S6 and S10 bind to full-length FnBPA and to an N-terminal fragment of FnBPA but not a C-terminal fragment of FnBPA (Figs. 4B-C) . Furthermore, antibody S4 bound moderately to superantigen-like protein 5 (SSL5), a secreted virulence factor that inhibits neutrophil migration (Fig. 4A) [31, 32] .
A large majority of healthy and infected individuals contain serum reactive to S. aureus peptidoglycan (PGN) and lipoteichoic acid (LTA) [7, 33] . ELISAs using purified S. aureus PGN and LTA revealed that S6 bound robustly to PGN, while antibodies S2 and S5 bound weakly (Fig. 5A) , and S3 bound strongly to LTA (Fig. 5B). 3.6. Antibodies that bind to S. aureus differentially promote opsonization and killing of S. aureus A major way in which antibodies protect against pathogens is through opsonization, a process in which antibodies coat the pathogen and thus mark it for ingestion and destruction by phagocytes. We used undifferentiated THP1 (human monocyte-like) cells and CFSE-labeled inactivated S. aureus to test whether the recombinant antibodies that bound to surface S. aureus proteins could function as opsonins. Using positive and negative control antibodies and halting the assay at 30-minute intervals allowed us to optimize the duration of the assay (Supplemental Fig. S4A ). We found that S3 and S8 promoted phagocytosis of S. aureus at the early-log growth phase (Fig. 6A) , whereas only S3 promoted phagocytosis of S. aureus at the stationary phase (Fig. 6C) . Antibodies S6 and S10 promoted phagocytosis of S. aureus grown in the presence of fibroblasts (Fig. 6E and Supplemental Fig. S4B ). Blocking FcγRs with FcR Block before co-incubation of monocytes and bacteria abrogated the antibody-induced increase in phagocytosis, confirming that S3, S6, S8, and S10 function as opsonins (Figs. 6B, D, F,  Supplemental Fig. S4B) . Notably, antibody S2, which bound to early-log phase bacterial lysate with the second highest intensity in the dot-blot screen, did not enhance internalization of S. aureus cells (Fig. 6E) .
To test the antibacterial activity of the recombinant antibodies, we incubated them with live S. aureus and differentiated HL-60 (human neutrophil-like) cells and evaluated any antibody-associated decreases in formation of bacterial colonies, as a measure of the antibodies' antibacterial activity. The S. aureus-binding antibody S6 reduced colony formation, whereas the S. aureus-binding antibody S2 and a flu-specific control antibody did not (Fig. 6G) . a Recombinant monoclonal IgG antibodies were generated from two patients with S. aureus infections. S2, S3, S8, S9, and S10 were derived from patient 1. S1, S4, S5, S6, and S7 were derived from patient 2.
b Mutations of the heavy-and light-chain V and J segments were obtained from IMGT. c LTA = lipoteichoic acid; SSL5 = superantigen-like protein 5; FnBPA = fibronectin-binding protein A; PGN = peptidoglycan.
Discussion
In this study, we use a novel barcoding method that we developed for the full-length sequencing of the paired V H and V L antibody sequences expressed by individual plasmablasts. This method, through cell-specific barcoding of mRNA, further enables us to bioinformatically index the reads recovered from high-throughput sequencing to a given cell to accurately determine the proportion of B cells with shared V(D)J sequences and somatic mutations, thereby correcting for biases in amplification that may occur during library amplification, emulsion PCR or sequencing. This accurate determination of frequently used antibody rearrangements and similar somatic mutations enables accurate identification of clonal plasmablast populations as well as highly selected somatic mutations. In addition, template-switch addition of well-ID barcodes and the hybridization of plate-ID barcodes onto universal adapter oligonucleotide at the 5′ end of the well-ID barcodes avoids the need for degenerate V-region primers which may fail to amplify certain allelic variants or highly mutated V-regions, and thereby provide unbiased hybridization of PCR primers. of plasmablast clonal families, but also to recombinantly produce relevant monoclonal antibodies secreted by plasmablasts and thus to characterize the binding and functional properties of endogenous antibodies generated in human immune responses to S. aureus infection. Previous high-throughput methods for evaluating antibody repertoires have largely focused on the sequence diversity of V H or heavy-chain CDR3 regions [10] [11] [12] , precluding characterization of the binding and functional properties of the specific individual antibodies generated by each cell. Other methods that sequence paired V H and V L [12, 34] do not sequence through the full-length V-region, and as a result necessitate surrogate, non-native V-region sequences for recombinant antibody expression. Our method, through barcoding of all the cDNA generated by each individual B cell, enables identification and matching of the cognate heavy-and light-chain antibody sequences expressed by the same cell, and thereby the recombinant production of the bona fide antibody expressed by that cell. Recombinant antibody production enables binding and functional analyses of the expressed antibodies in the absence of other blood antibodies, an advantage over approaches based on analysis of serum antibodies [35] .
We used this approach to identify the antibodies expressed by plasmablasts generated in S. aureus bacteremic individuals, and to use the recombinant antibody products to determine whether they bind and/or kill S. aureus. Seven of the ten (70%) recombinant antibodies derived from two S. aureus-infected individuals bound to S. aureus. This percentage is similar to the findings of previous studies that investigated plasmablast specificity against vaccine protein antigens and viral peptides [9, 8] . The high percentage of S. aureus-specific antibodies from families with shared IGHV and IGHJ usage suggests that the analysis of antibody families can facilitate identification of candidate immunoglobulin rearrangements and somatic hypermutations preferentially selected for during infection. This also suggests that characterization of antibodies expressed by plasmablasts, the population of activated B cells present in an immune response, may provide a strategy to identify antibodies targeting the critical antigenic determinants in an anti-microbial immune response. Further studies with additional S. aureus-infected patients or other infectious diseases will be necessary to elucidate whether antibodies produced by rapidly expanding B-cell populations are most relevant to the containment of infection.
Of the seven antibodies that bound to S. aureus, four enhanced S. aureus opsonization. Pro-opsonophagocytic antibodies S6 and S10, which were derived from separate patients, both bound to an extracellular region of FnBPA away from its fibronectin-binding domains and C-terminal membrane-spanning domain [36] , suggesting that these antibodies can recognize FnBPA and mediate opsonization even when it is bound to fibronectin. These antibodies also bind away from the FnBPA fibronectin-binding domain repeats, which are known to exhibit inter-strain variance [37] . The finding that two antibodies containing unique germline gene segments from different patients both bound to the FnBPA N-terminus suggests that the FnBPA N-terminus may be an immunodominant epitope during S. aureus bacteremia. Further analysis is necessary to determine whether the epitopes recognized by these antibodies are conserved across multiple bacterial strains. Antigens targeted robustly by multiple patients with favorable clinical outcomes may be useful for vaccine design.
In contrast, antibody S2, which also bound S. aureus, didn't promote opsonophagocytosis or bacterial killing. Emerging evidence reveals that antibodies that bind to S. aureus antigens can fail to promote opsonophagocytic killing independent of staphylococcal evasion mechanisms [38, 39] , which may be due to an antibody binding orientation that masks the accessibility of the Fc domain. This underscores the utility and need for recombinant antibody-enabled functional analyses. aureus Wood46 were incubated with antibodies and activated HL-60 neutrophils. Bacteria were plated following HL-60 lysis, and mean percent decrease in CFU was measured. Flu-specific antibodies F14 and F26 were used as isotype controls. op = anti-S. aureus polyclonal rabbit IgG antibodies. Data are from three experiments performed on separate days and are presented as mean values of all replicates ± s.e.m. Statistical significance was determined by using two-tailed unpaired t-tests; n.s., not significant (P N 0.05); *P b 0.05; **P b 0.01; ***P b 0.001.
Multiple recombinant plasmablast antibodies bound to non-protein S. aureus antigens PGN and LTA. The majority of plasmablasts in peripheral blood are believed to differentiate from B-cell precursors that have undergone conventional CD4+ T-cell-dependent activation and somatic hypermutation in B-cell follicles, and are therefore specific for protein antigens and zwitterionic polysaccharides. Marginal zone and B1 B cells are important in the immune response against bloodborne pathogens and can circulate in the blood as plasmablasts; however, their immunoglobulin genes are believed to undergo limited somatic hypermutation and antibodies secreted by these B-cell subsets show limited evidence of affinity maturation. Interestingly, the sequence analysis revealed that all antibodies had high mutation numbers ( Table 1 ), suggesting that the plasmablasts expressing these antibodies were activated by uncharacterized mechanisms of T-cell-dependent activation or that some extrafollicular B cells may undergo considerable affinity maturation that has not previously been appreciated.
As anticipated, all recombinant antibodies bound to IgG-binding proteins A and Sbi in the antigen microarrays (data not shown), which are believed to have a role in bacterial evasion of the host immune system by disrupting opsonization and complement fixation [36, 40] . Protein Sbi has also been implicated in immune evasion through the degradation of C3 [41] . Further tests with Fab fragments are required to determine whether the antibodies bind specifically to protein Sbi. That S2, S5, and S8 did not bind to any proteins on the microarray could be because of inter-strain variation. Also, the cell-free Rapid Translation System used for expressing the S. aureus proteins for the microarray may have unexpectedly altered the conformation of certain S. aureus proteins, masking epitopes normally recognized by these antibodies.
There were several technical limitations to the approach used in this study. Selection of antibodies for recombinant expression on the basis of shared gene segments did not include antibodies with different sequences sharing CDR protein structures and potentially similar binding properties. In addition, the limited sequencing depth per patient may have prevented detection of sequences representing small clonal families. Future studies sequencing additional patients and plasmablasts per patient will be necessary to elucidate clonal family frequencies and identify clonal families shared between multiple patients.
The efficient recovery of anti-S. aureus reactive antibodies from peripheral blood plasmablasts derived from S. aureus bacteremic humans indicates that this approach can efficiently and effectively reveal antigens targeted by the anti-microbial B cell response. This strategy can be leveraged to identify and isolate valuable diagnostic and therapeutic antibodies, to monitor the status of the humoral immune response over the course of infection, and to determine critical epitopes for vaccine design and monitoring.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.clim.2014.02.010.
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